AJDRAJNR - American Journal of Neuroradiology

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sze, G.
Right arrow Articles by Goldstein, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sze, G.
Right arrow Articles by Goldstein, H.

American Journal of Neuroradiology, Vol 11, Issue 5 967-974, Copyright © 1990 by American Society of Neuroradiology


ARTICLES

Multicenter study of gadopentetate dimeglumine as an MR contrast agent: evaluation in patients with spinal tumors

G Sze, GK Stimac, C Bartlett, WP Dillon, VM Haughton, W Orrison, F Kashanian and H Goldstein
Department of Medical Imaging, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.

In an open-label, multicenter study, the efficacy and safety of gadopentetate dimeglumine (0.1 mmol/kg) administered IV as an MR imaging contrast agent were evaluated in 113 patients with symptoms of spinal tumors. The examinations were performed with a variety of imagers at different field strengths. Scans with short and long TRs were obtained in all patients before and after IV administration of the contrast medium. Contrast enhancement was seen in 77% of patients. No enhancement was seen in 23%, but this absence was useful diagnostic information in all cases. In 66% of the cases, additional information regarding location, size, configuration, and/or characterization of the lesion was obtained from postcontrast scans. The investigators made a change from referral diagnosis to postinjection diagnosis in 30% of the cases. Postinjection images provided additional information in 96% (43/45) of intradural extramedullary and intramedullary tumors; it also provided additional information in 20 (53%) of 38 cases of extradural tumor. Gadopentetate dimeglumine demonstrated a high level of safety and tolerance, as evidenced by the lack of clinically significant trends toward abnormal changes from baseline evaluations for physical and neurologic examinations, vital signs, and hematologic and blood chemistry parameters and by the low prevalence and mild nature of adverse reactions. Gadopentetate dimeglumine was found to be efficacious in the evaluation of suspected spinal tumors. High levels of safety and tolerance were demonstrated.


This article has been cited by other articles:


Home page
RadioGraphicsHome page
K. K. Koeller, R. S. Rosenblum, and A. L. Morrison
Neoplasms of the Spinal Cord and Filum Terminale: Radiologic-Pathologic Correlation
RadioGraphics, November 1, 2000; 20(6): 1721 - 1749.
[Abstract] [Full Text] [PDF]